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Abstract: PURPOSE Open fetal spina bifida repair has become a novel clinical standard of care. In very
large spina bifida lesions, the skin defect cannot be covered primarily, asking for alternative solutions. We
hypothesize that amniotic fluid stem cells (AFSC) could be differentiated into keratinocytes that could
then be used to bioengineer autologous skin usable for in utero back coverage. METHODS To obtain
human AFSC, amniotic fluid samples obtained from fetal surgeries were subjected to immunoselection for
c-kit. C-kit-positive samples and controls were cultured with the additives morphogenetic protein 4 and
vitamin C to induce differentiation towards keratinocytes. This process was monitored by measuring the
expression of K8 and K14 via immunohistochemical staining, flow cytometry, and polymerase chain reac-
tion. RESULTS After immunoselection and expansion, most cells were positive for K8, but none for K14.
After completion of the differentiation protocol, cell colonies with keratinocyte-like appearance could be
observed, but cells remained positive for K8 and negative for K14, indicating failed differentiation into
keratinocytes. CONCLUSIONS Culturing of keratinocyte-like cells from AFSC, harvested intraopera-
tively, was not feasible in this setting. The reasons for failure must be investigated and eliminated, as
bioengineering of fetal skin for clinical use during fetal surgery for spina bifida remains an attractive goal.
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Abstract
Purpose: Open fetal spina bifida repair has become a novel 
clinical standard of care. In very large spina bifida lesions, the 
skin defect cannot be covered primarily, asking for alterna-
tive solutions. We hypothesize that amniotic fluid stem cells 
(AFSC) could be differentiated into keratinocytes that could 
then be used to bioengineer autologous skin usable for in 
utero back coverage. Methods: To obtain human AFSC, am-
niotic fluid samples obtained from fetal surgeries were sub-
jected to immunoselection for c-kit. C-kit-positive samples 
and controls were cultured with the additives morphoge-
netic protein 4 and vitamin C to induce differentiation to-
wards keratinocytes. This process was monitored by measur-
ing the expression of K8 and K14 via immunohistochemical 
staining, flow cytometry, and polymerase chain reaction. Re-
sults: After immunoselection and expansion, most cells 
were positive for K8, but none for K14. After completion of 
the differentiation protocol, cell colonies with keratinocyte-
like appearance could be observed, but cells remained posi-
tive for K8 and negative for K14, indicating failed differentia-
tion into keratinocytes. Conclusions: Culturing of keratino-
cyte-like cells from AFSC, harvested intraoperatively, was not 
feasible in this setting. The reasons for failure must be inves-
tigated and eliminated, as bioengineering of fetal skin for 
clinical use during fetal surgery for spina bifida remains an 
attractive goal. © 2019 S. Karger AG, Basel
Introduction
Open spina bifida (OSB) is a frequent congenital mal-
formation that causes a disastrous and irreversible cluster 
of neurological impairments in affected individuals. Ana-
tomically, OSB is characterized by a localized closure de-
fect of the developing spinal cord (non-neurulation), me-
ninges, vertebral arches, overlaying muscles, and skin. 












































































to the amniotic fluid and uterine wall. Studies have shown 
that especially in the third trimester of gestation, the un-
protected spinal cord is progressively injured by mechan-
ical trauma and by toxic effects of the amniotic fluid 
(“two-hit hypothesis”) [1]. Early protection of exposed 
neural tissue by fetal surgery was shown to prevent this 
injury in experimental studies [2], and finally, a prospec-
tive randomized clinical trial (MOMS trial [3]) demon-
strated significantly better results in infants after fetal 
than after postnatal repair. Fetal OSB repair has therefore 
become a new clinical standard of care for select human 
fetuses suffering from this devastating malformation. 
Within the phenotypic spectrum of OSB, some lesions 
are very large, and, consequently, the skin defect cannot 
be primarily closed, requiring alternative approaches. In 
this context, we have pioneered the use of biosynthetic 
skin substitutes [4] and also the in utero construction of 
transposition flaps [5], both of which are tenable ways to 
go. Yet, disadvantages include a necessity for postnatal 
skin grafting or formal flap closure of donor sites.
In search of potentially better solutions, we hypothe-
sized that bioengineering and in utero application of fetal 
skin might be an elegant solution.
Our research group has already conducted various ex-
periments to engineer and transplant fetal dermoepider-
mal skin substitutes (fDESS): We showed that using small 
fetal skin biopsies, fDESS could be successfully bioengi-
neered in the laboratory [6] and grafted in vivo onto im-
munoincompetent rats [7]. Lastly, we successfully trans-
planted autologous fDESS in utero onto sheep fetuses 
(manuscript in preparation). Of note, a first step towards 
tissue engineering of a fDESS without the need of a skin 
biopsy was published by our group earlier, showing that 
amniotic fluid mesenchymal cells could be used instead 
of fibroblasts to build the dermal part of a fDESS [8].
Here, we report on our attempt to stimulate amniotic 
fluid stem cells (AFSC) to differentiate into keratinocytes 
(KC) that could then be used to bioengineer fetal skin for 
eventual clinical application. 
Materials and Methods
Human amniotic fluid samples were obtained during human 
fetal surgeries for OSB right after opening the uterus. Care was 
taken to minimize sample contamination by maternal blood. We 
used amniotic fluid samples from 5 fetal surgeries (gestational ages 
between 24 and 25 weeks). All amniotic fluid samples were ex-
panded on glass cover slides for 10 days in Chang B+C medium® 
(Irvine Scientific). Selection of AFSC and differentiation into KC 
were done as described by Sun et al. [9]. Briefly, once growing of 
mesenchymal appearing cell colonies was observed, immunoselec-
tion for c-kit with the MACS system (Miltenyi Biotec) and subse-
quent expansion in nontreated 24-well multidishes in the Chang 
complete medium® (MEM Alpha containing 20% Chang B+C, 
15% fetal bovine serum, penicillin, and streptomycin [5 per 500 mL 
medium] and L-glutamine [2 mM final]) was performed. Cells were 
checked daily for morphology, and the medium was changed three 
times per week. When cells reached 70% confluence, they were 
trypsinized and seeded onto uncoated 35-mm dishes. Cells were 
transferred to 6-well culture dishes at a seeding density of 2 × 104 
cells per well after passage 3 and were differentiated in KBMTM-2 
Basal Medium (Lonza) with additional supplements (10% fetal bo-
vine serum, 10 ng/mL recombinant human EGF [R&D Systems, 
Minneapolis, MN, USA], 0.5 nM human recombinant BPM-4 
[R&D Systems], 50 μg/mL ascorbic acid [Sigma-Aldrich], 5 μg/mL 
insulin [Sigma-Aldrich], 0.5 μg/mL hydrocortisone [Sigma-Al-
drich], 0.1 nM cholera toxin [Sigma-Aldrich], 1.37 ng/mL triiodo-
thyronine [Sigma-Aldrich], 24 μg/mL adenine [Sigma-Aldrich]), 
and KC-conditioned medium in a 1: 1 ratio for 30 days.
For control, samples of c-kit-negative fractions and samples 
without immunoselection were cultured analogously.
Monitoring
Cells were monitored at regular time intervals for keratin 8 
and keratin 14 expression. The percentage of cells that express 
K8 or K14, respectively, was determined either by flow cytome- 
try or by immunohistochemistry (K8: clone K8.8, 1: 100, K14: clone 
EP1612Y1: 500; Abcam), which also allowed to observe cell mor-
phology. Nuclei were stained with 1 μg/mL Hoechst 33341 (Sig-
ma). As positive controls for K14, either HaCaT cells or human KC 
from full skin biopsies were used. For polymerase chain reaction 
(PCR) analysis, cells of some culture plates were collected in sus-
pension and frozen in liquid nitrogen at different stages of differ-
entiation. PCR was performed simultaneously on all samples using 
primers for K5/K14 and K8/18.
Results
At the first medium change after 7 days, plates revealed 
cell colonies of different morphologies, some with mes-
enchymal and others with epithelial appearance (Fig. 1). 
Only few cells could be detected microscopically after im-
munoselection for c-kit with the MACS® system. Cell 
morphology and composition after expansion of these 
cells did not show any striking difference compared to c-
kit-negative and unselected amniocyte cultures. In addi-
tion, the c-kit-positive, c-kit-negative, and unselected 
amniocyte cultures remained morphologically undistin-
guishable during the whole differentiation period. 
Immunohistochemistry showed that the majority of 
cells in all cultures were positive for K8 (a marker of 
simple, not stratified epithelia) (Fig. 2), suggesting opti-
mal preconditions for epithelial differentiation, but no 













































































Furthermore, after having completed the 30-day dif-
ferentiation protocol, both, the c-kit-positive and -nega-
tive cell fractions were not different in terms of morphol-
ogy, growth characteristics, or immunohistochemical 
staining. Several culture plates contained cells with a KC-
like morphology, as seen in Figure 3. The c-kit-negative 
population exhibited a morphology similar to the cobble-
stone appearance of KC. While most cells were still posi-
tive for K8, K14-positive cells were not found.
PCR and flow cytometry results of different samples 
during the differentiation process yielded identical find-
ings: the amount of K8-positive cells varied; however, 
keratin14 was not expressed (data not shown).
With increasing passage (up to p10–13), proliferation 
of cells decreased, and cells started to detach, likely be-
cause of senescence.
Discussion
The hypothesis that amniotic fluid might be a valuable 
repository for stem cells that could be used to create close 
to normal autologous fetal skin is highly attractive. This 
is especially true for the clinical scenario of large defects 
in fetal spina bifida repair where direct skin closure is not 
possible and some sort of substitutes are needed. As all 
patients planned for fetal spina bifida repair do undergo 
preoperative amniocentesis to exclude genetic anomalies, 
amniotic fluid would always be available. Therefore, the 
goal of this study was to differentiate AFSC into KC that 
could then be used to bioengineer autologous skin for in 
utero back coverage of large spina bifida defects.
The results of the study show that after immunoselec-
tion and completion of the differentiation protocol, we 
did obtain cell colonies with KC-like appearance in both 
c-kit-positive and -negative fractions. However, these 
a b
Fig. 1. Mesenchymal (a) and epithelial (b) appearance of human amniocytes on glass cover slides after 7 days in the preselection me-
dium (Chang B+C Medium). Bars = 100 µm.
Fig. 2. Immunohistochemistry of amniotic fluid cells staining pos-
itive for K8 (orange, Alexa Fluor® 555) during differentiation. 
These cells were selected for c-kit. Nuclei stained with Hoechst 












































































cells were simple epithelial cells, as shown by immunos-
taining (i.e., positive for cytokeratin K8) and they were 
lost after several passages, most likely due to senescence. 
Thus, within the particular setting of our experiments, it 
was not possible to obtain classical KC from AFSC. 
Interestingly, other groups have performed similar ex-
periments yet with other goals and were able to show that 
AFSC can be successfully differentiated into cell lines of 
all three germ layers [10], and in particular also into KC 
[9]. As in these quoted studies, our experiments were also 
based on the same two pillars: the isolation of AFSC by 
selection for c-kit and the use of bone morphogenetic 
protein 4 (BMP-4) and ascorbic acid (vitamin C [VitC]) 
for the differentiation into KC.
De Coppi et al. [10] described the isolation of AFSC 
using selection for c-kit (CD117), obtaining 1% of cells 
that were pluripotent stem cells capable of differentiating 
into lineages of the three embryonic germ layers. AFSC 
were shown to exhibit intermediate characteristics be-
tween embryonic stem cells and mesenchymal stem cells 
[11]. However, Arnhold et al. [12] compared c-kit-posi-
tive cell fractions with c-kit-negative and nonselected 
populations and found that the neuronal differentiation 
potential was higher in the c-kit-negative fraction. Al-
a b
c d
Fig. 3. Different amniocyte fractions after the 30-day differentiation protocol in KGMTM-2 (all bars = 100 µm). 
a Amniocytes from the c-kit-negative fraction after 2 weeks in KGM-2 (p1). b Amniocytes from the c-kit-posi-
tive fraction after 2 weeks in KGM-2 (p2). c Amniocytes from samples without c-kit immunoselection after 2 












































































though this was never examined, based on the common 
neuroectodermal origin of neurons and KC, one could 
deduce from Arnhold’s results that also epidermal differ-
entiation should be higher in the c-kit-negative fraction. 
We therefore also used the c-kit-negative fraction in our 
experiments. Sun et al. [9] were the first to describe dif-
ferentiation of AFSC into KC, isolating AFSC as described 
by De Coppi [10] with c-kit selection and then using 
BMP-4 and VitC during the differentiation process. 
Movahednia et al. [13] reviewed several studies on the 
differentiation of embryonic stem cells into KC. Most of 
these studies used BMP-4, which is an inhibitor of neural 
differentiation into embryonic stem cells at some point 
during differentiation. Guenou et al. [14] added ascorbic 
acid to the use of BMP-4. Ascorbic acid is known to act as 
a radical scavenger and to promote KC survival [15]. We 
used both BMP-4 and VitC as described by Sun and ap-
plied it to c-kit-positive, c-kit-negative, and unselected 
cultures. The differentiation progress was monitored by 
the mean of observing transition of expression of K8/18 
to K5/14, as it was described for studies differentiating 
embryonic stem cells into KC [14] and also by Sun et al. 
[9]. K8/18 form heteropolymeric intermediate filaments 
in simple epithelia. They are the first keratins that appear 
in embryogenesis but disappear in differentiating KC and 
are normally not present in the stratified epidermis [16]. 
K5 and K14 are heteropolymers that make up the intra-
cellular cytoskeletal scaffold of the basal KC in a stratified 
epidermis [17]. Despite adherence to the concepts and 
protocols of the above-mentioned studies, we could not 
observe any epidermal differentiation; i.e., the transition 
of K8/18 expression to K5/14, whether by immunohisto-
chemistry nor flow cytometry and PCR. 
In light of the published successful “creation” of ecto-
dermal cells [10] and specifically KC [9], possible causes 
for failure in our setting were analyzed. One distinct dif-
ference between the successful AFSC experiments and 
our setting was found: the source of amniotic fluid used. 
In our assays, we used amniotic fluid from open fetal sur-
geries (access to the uterine cavity by hysterotomy). This 
source entails several possible pitfalls. First, the amniotic 
fluid was often contaminated with maternal blood and 
cell detritus. This hampered the observation of cell mor-
phology during the first 5 days, and we do not know 
whether cell detritus and blood constituents had a nega-
tive influence on AFSC; e.g., by disturbing their attach-
ment. Second, amniotic fluid of a pregnancy with spina 
bifida might result in a different response of the AFSC to 
the differentiation protocol. Ceccarelli et al. [18] showed 
that sheep AFSC in myelomeningocele models exhibit 
different gene expression patterns and metabolic varia-
tions compared to those of healthy fetuses. Third, the 
amniotic fluid we used was of advanced gestational age 
(between 24 and 25 weeks). Moschidou et al. [19] report-
ed a higher fraction of pluripotent cells in amniotic fluid 
of lower gestational age. Prior studies have suggested 16–
22 weeks to be the optimal gestational age for good-qual-
ity amniotic fluid to isolate c-kit-positive stem cells. The 
gestational age of these samples varied between 16 and 
31 weeks [20]. Similarly, Sun et al. [9] used amniotic flu-
id samples ranging from 19 to 22 weeks of gestation to 
differentiate KC from amniotic fluid. One study com-
pared markers of amniotic fluid cells by real-time PCR at 
weekly time points between 15 and 20 weeks gestational 
age and found c-kit to disappear at 19–20 weeks [21]. 
This is lower than the suggested 16–22 weeks for optimal 
c-kit sampling by a different group [20]. Another study 
showed that second-trimester amniotic fluid did not re-
veal any c-kit-positive cells in a fluorescence-activated 
cell sorting analysis, but many other pluripotency mark-
ers [22]. Hence, a limitation of our study was to rely sole-
ly on c-kit expression, since it may no longer have been 
expressed at the gestational age of our amniotic fluid 
samples.
Unfortunately, we were not able to use amniotic fluid 
from amniocenteses of earlier gestational ages and from 
pregnancies without OSB. Due to the increasing use of 
noninvasive pregnancy testing, amniocentesis in general 
is performed less often, resulting in sample paucity for 
research purposes. The preoperative amniocentesis sam-
ples from our fetal surgery patients were all used for di-
agnostic purposes and were not available to us for this 
experimental line. However, we are convinced that these 
same experiments must be repeated with both amniocen-
teses samples from patients carrying a fetus with OSB and 
from pregnancies with healthy fetuses, obtained earlier in 
gestation.
Another pertinent point that deserves a comment is 
whether the duration needed to differentiate KC from 
AFSC does allow a clinical use for the envisioned scenar-
io. Although OSB is typically diagnosed in the second tri-
mester, in expert hands it can also be reliably detected 
early in gestation during the 11–14 weeks screening [23, 
24]. If amniocentesis is performed at 15 weeks, up to 10 
weeks remain for the bioengineering process, as fetal OSB 
repair is performed at 23–26 weeks. The differentiation 
process has been reported to last 30 days [9]; thereafter, 
5–6 weeks remain for expansion and application in the 
organotypic cultures. Based on this calculation, the envi-












































































However, for reasons considered above, particularly 
the aspects of different gene expression patterns and 
metabolic variation in AFSC of OSB samples, the envi-
sioned goal may be unreachable. More generally, our 
findings also prompt interesting new questions: do se-
vere congenital malformations, particularly those with a 
large abnormal body opening towards the amniotic cav-
ity (e.g., OSB with outflow of fetal cerebrospinal fluid, 
gastroschisis, and omphalocele) influence AFSC in any 
significant way? 
Last, although the immature immune system of the 
fetus might tolerate also allogeneic KC obtained from 
other sources, the readily available amniotic fluid in pa-
tients planned to have fetal OSB repair remains an attrac-
tive source to investigate on.
Conclusion
Differentiation of AFSC into phenotypically classical 
KC failed in our setting. The specific amniotic fluid source 
in our study; i.e., amniotic fluid from fetal surgery, is seen 
as the most likely reason for failure. Follow-up experi-
ments using autologous amniotic fluid harvested earlier 
in gestation by amniocentesis may solve the current prob-
lem and ultimately allow culturing of a close-to-natural 
epidermis suitable for clinical application in utero.
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